IXICO has completed a fundraising
March 2026 — IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a gross capital raise of US$13.5 million. The funds will be used to support the company’s tech bio strategy, enabling IXICO to partner its platform more broadly and maximize its potential.
IXICO plc is a precision neuroscience company. Its AI-enabled neuroimaging platform supports clinical trials for neurological diseases, including Alzheimer’s and Huntington’s disease, helping biopharmaceutical companies make better and faster decisions in drug development.
Our role in the transaction
Oaklins Cavendish, one of Oaklins’ member firms in the UK, acted as the sole bookrunner and broker for IXICO plc’s US$13.5 million capital raise.
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreTandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn moreICOP has transferred its listing from Euronext Growth Milan to Euronext Milan
ICOP S.p.A. has transferred its listing from Euronext Growth Milan to Euronext Milan.
Learn more